文献速递临床试验与 GCP

恢复研究PRGF:富血小板生长因子治疗膝骨关节炎的随机临床试验

Restoring Study PRGF: a randomized clinical trial on plasma rich in growth factors for knee osteoarthritis.
PubMed 文献 · Trials · 2023-01-18

该研究基于未发表的研究方案和最终报告重新分析了PRGF对比透明质酸治疗膝骨关节炎的随机试验。预设主要和次要疗效终点均无统计学差异;主要终点WOMAC疼痛评分下降>40%的患者比例PRGF组较透明质酸组高5.4%(95%CI -10.4%至21.3%,p=0.505)。原文报告的全部不良事件48小时内消失与未发表材料不符。

要点

  • 预设主要终点WOMAC疼痛下降>40%:PRGF组较透明质酸组高5.4%(95%CI -10.4%至21.3%,p=0.505),无统计学差异。
  • 未预设终点WOMAC疼痛下降>50%:原文报告PRGF组较透明质酸组高14.1%(95%CI 0.5至27.6%,p=0.044)。
  • 至少2例透明质酸组和5例PRGF组患者报告持续性不良事件,与原文全部不良事件48小时内消失的表述不符。

核心结论

  • 重新分析未发现PRGF较透明质酸在膝骨关节炎治疗中有临床或统计学显著获益。
  • 恢复研究PRGF表明试验报告和监督实践亟需重要改变。
  • 未来需要及时获取所有临床试验文件以尽量减少报告偏倚风险。
  • 伦理委员会应在出现潜在不端行为时随时准备干预。

研究设计与样本

  • 基于未发表的研究方案和最终报告对原始随机临床试验进行重新分析,原试验于2007年12月19日由西班牙巴斯克地区伦理委员会批准并注册为BTI-01-EC/07/ART。
  • 重新分析聚焦于提供疗效和安全性的更新分析。

主要发现

  • 预设主要终点WOMAC疼痛评分下降>40%的患者比例PRGF组较透明质酸组高5.4%(95%CI -10.4%至21.3%,p=0.505)。
  • 原文报告的非预设主要终点WOMAC疼痛评分下降>50%的患者比例PRGF组较透明质酸组高14.1%(95%CI 0.5至27.6%,p=0.044)。
  • 至少2例透明质酸组和5例PRGF组患者报告持续性不良事件。
  • 原文存在利益冲突披露不充分的问题。

关键数值与推荐

  • 预设主要终点:WOMAC疼痛评分下降>40%的患者比例,PRGF组较透明质酸组高5.4%(95%CI -10.4%至21.3%,p=0.505)。
  • 原文非预设主要终点:WOMAC疼痛评分下降>50%的患者比例,PRGF组较透明质酸组高14.1%(95%CI 0.5至27.6%,p=0.044)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A randomized clinical trial assessing plasma rich in growth factors (PRGF) versus hyaluronic acid for knee osteoarthritis was published in 2012 (sponsor trial ID BTI-01-EC/07/ART). Evidence of misreporting was discovered following access to unpublished materials. In accordance with the principles of the Restoring Invisible and Abandoned Trials (RIAT) initiative, we sought to re-analyse Study PRGF based on the unpublished trial materials. METHODS: Reanalysis was made possible primarily based on two unpublished study documents (original trial protocol and final report) obtained from the authors of the original publication. A call to action, calling on the authors to correct the original publication, was publicly issued. The involved ethics committee was repeatedly approached and extensive discussion with the authors ensued. After no agreement to correct the paper was reached, we embarked on this restoration. Reanalysis was focused on providing updated analyses for efficacy and safety. RESULTS: The efficacy of PRGF was not statistically different from hyaluronic acid for any prespecified primary or secondary efficacy outcomes. For the primary endpoint, the percent of patients on PRGF compared to hyaluronic acid with a decrease >40% in WOMAC pain subscale score was 5.4% higher; 95% confidence interval (CI) -10.4% to 21.3%; p = 0.505. This differs from the original publication that reported a non-prespecified primary endpoint (decrease >50% in WOMAC pain subscale score) which was 14.1% higher; 95% CI 0.5 to 27.6%; p=0.044. Furthermore, in contrast to the article statement that all the adverse events disappeared in 48 h, at least two patients in the hyaluronic arm and five patients in the PRGF arm reported persistent adverse events. Inadequate disclosure of conflicts of interest in the original publication was also noted. CONCLUSIONS: This reanalysis of Study PRGF found no clinically or statistically significant benefit from PRGF compared to hyaluronic acid. The restoration of Study PRGF shows the urgency of important changes to trial reporting and oversight practices. In the future, timely access to all clinical trial documents is needed to minimize the risk of reporting bias. Similarly, ethics committees should be ready to intervene whenever a case of potential misconduct arises. TRIAL REGISTRATION: This is a RIAT project, whose original trial was approved and registered on 19 December 2007 by the Ethics Committee of the Basque Country, Spain, as BTI-01-EC/07/ART.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Saiz LC, Erviti J, Leache L, et al. Restoring Study PRGF: a randomized clinical trial on plasma rich in growth factors for knee osteoarthritis. Trials. 2023. PMID: 36653802. doi:10.1186/s13063-022-07049-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。